Showing results (2011-2020 of 2,436) with videos related to

Sort By:
Pageof 244
European Journal of Cancer (Oxford, England : 1990)|March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohortRoberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2023
Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammationGianluca Scarno, Julija Mazej, Mattia Laffranchi, et al.
American Journal of Human Genetics|May 14, 2019
Bi-allelic Variants in DYNC1I2 Cause Syndromic Microcephaly with Intellectual Disability, Cerebral Malformations, and Dysmorphic Facial FeaturesMuhammad Ansar, Farid Ullah, Sohail A Paracha, et al.
Clinical & Experimental Metastasis|September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 datasetAlessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Expert Review of Anticancer Therapy|April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
Targeted Oncology|July 29, 2026
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)Mimma Rizzo, Sebastiano Buti, Ondřej Fiala, et al.
Frontiers in Bioscience (Elite Edition)|September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic ScoreGiulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Oncotarget|March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinomaDaniele Santini, Matteo Santoni, Alessandro Conti, et al.
Pageof 244